Physician profile
Vivek Misra
NPI 1255542049
$1,259.46
in general payments reported to CMS, 2019-2025
21 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $87.75 · 2021: $339 · 2022: $183 · 2023: $143 · 2024: $116 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $193.61 | 2021-2022 | |
| Csl Behring | $137.54 | 2021-2023 | Kcentra |
| Portola Pharmaceuticals, LLC | $124.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $102.66 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $92.43 | 2019-2022 | |
| Ucb, INC. | $82.70 | 2024-2025 | Briviact |
| Otsuka America Pharmaceutical, INC. | $78.27 | 2023-2024 | Nuedexta |
| Astrazeneca Pharmaceuticals Lp | $77.51 | 2022-2023 | |
| Genzyme Corporation | $68.87 | 2025 | |
| Pfizer INC. | $50.45 | 2019-2021 | |
| Amgen INC. | $44.95 | 2019-2024 | Repatha |
| Saol Therapeutics INC. | $28.99 | 2020 | |
| Biogen, INC. | $27.42 | 2021-2025 | Tysabri, Vumerity |
| Abbvie INC. | $26.57 | 2024 | |
| Boston Scientific Corporation | $25.70 | 2025 | Bodyguardian |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.91 | 2025 | |
| Grt US Holding, INC. | $17.09 | 2020 | |
| Genentech USA, INC. | $16.07 | 2020 | |
| Gilead Sciences, INC. | $15.11 | 2022 | |
| Microtransponder, INC. | $13.84 | 2023 | |
| Chiesi USA, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.